Skip to main content

Peer Review reports

From: Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

Original Submission
18 Apr 2022 Submitted Original manuscript
25 Apr 2022 Author responded Author comments - Adam Hermawan
2 Jun 2022 Reviewed Reviewer Report
17 Jul 2022 Reviewed Reviewer Report
5 Aug 2022 Author responded Author comments - Adam Hermawan
Resubmission - Version 2
25 Apr 2022 Submitted Manuscript version 2
6 Aug 2022 Author responded Author comments - Adam Hermawan
Resubmission - Version 3
6 Aug 2022 Submitted Manuscript version 3
8 Aug 2022 Author responded Author comments - Adam Hermawan
Resubmission - Version 4
8 Aug 2022 Submitted Manuscript version 4
14 Aug 2022 Reviewed Reviewer Report
26 Aug 2022 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
6 Sep 2022 Editorially accepted
16 Sep 2022 Article published 10.1186/s12863-022-01086-2

You can find further information about peer review here.

Back to article page